Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKN1 | Q16512 | 4/20 | 0.48 |
| ▸ | PAK4 | O96013 | 3/20 | 0.48 |
| ▸ | PAK1 | Q13153 | 4/20 | 0.44 |
| ▸ | PAK3 | O75914 | 2/20 | 0.44 |
| ▸ | PAK2 | Q13177 | 2/20 | 0.44 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.44 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 5/20 | 0.42 |
| ▸ | EGFR | P00533 | 2/20 | 0.42 |
| ▸ | WEE1 | P30291 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 3/20 | 0.39 |
| ▸ | BRD4 | O60885 | 3/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | BRD2 | P25440 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.39 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.39 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.39 |
| ▸ | KDR | P35968 | 2/20 | 0.39 |
| ▸ | STK4 | Q13043 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14693021 | 0.88 | PKN1 (0.50) | PKN1PAK4PAK1PAK3PAK2 | |
| SCHEMBL15041281 | 0.85 | PKN1 (0.51) | PKN1PAK4PAK1PAK3PAK2 | |
| SCHEMBL13553519 | 0.82 | PKN1 (0.57) | PKN1PAK4PAK1PAK3PAK2 | |
| SCHEMBL13553530 | 0.80 | PKN1 (0.56) | PKN1PAK4PAK1PAK3PAK2 | |
| SCHEMBL13553476 | 0.80 | PKN1 (0.64) | PKN1PAK4PAK1PAK3PAK2 | |
| SCHEMBL15035219 | 0.79 | PKN1 (0.65) | PKN1PAK4PAK1PAK3PAK2 | |
| SCHEMBL14684875 | 0.78 | PAK4 (0.52) | PKN1PAK4PAK1PAK3PAK2 | |
| SCHEMBL14681958 | 0.78 | PAK4 (0.52) | PKN1PAK4PAK1PAK3PAK2 | |
| SCHEMBL13553536 | 0.77 | PAK4 (0.51) | PKN1PAK4PAK1PAK3PAK2 | |
| SCHEMBL15030226 | 0.76 | PKN1 (0.63) | PKN1PAK4PAK1PAK3PAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120270866-A1 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | AFRAXIS INC. (US) | 2012-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270866-A1 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | PAK2, PAK6, PAK5 | PKN1 528/4885PAK4 6/4885PAK1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.